Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

University of Alabama at Birmingham Comprehensive Cancer Center

1824 Sixth Avenue, Wallace Tumor Institute, South Birmingham, AL 35294 - USA

The University of Alabama at Birmingham Comprehensive Cancer Center is the only National Cancer Institute-designated comprehensive cancer center located in a six-state area that includes Alabama, Arkansas, Georgia, Louisiana, Mississippi, and South Carolina.

From bench to bedside, the UAB Comprehensive Cancer Center is at the forefront of improving cancer prevention, diagnosis, and treatment. Researchers have pioneered advances in chemotherapy, surgery, radiotherapy, immunotherapy, and nutrition.

The UAB Comprehensive Cancer Center offers a full array of treatment options from multidisciplinary clinics filled with experts from across cancer fields to the latest technology. The center is home to more than 350 physicians and researchers, many of whom are internationally and nationally recognized for their expertise in oncology. The Cancer Center treats an estimated 5,000 new patients each year.

Website: The University of Alabama at Birmingham Comprehensive Cancer Center

Contact:
Freda Lewis
205-975-3742

Trials at this location:

BRE12-158

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.

Status: Open to Accrual
Read More

GU15-223

Randomized Phase II trial comparing sequential first-line sunitinib and second-line avelumab versus first-line avelumab and second-line sunitinib for metastatic renal cell carcinoma: SUAVE trial: HCRN GU15-223

Status: Open to Accrual
Read More

TBCRC035

Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)

Status: Open to Accrual
Read More